| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/11/2005 | CN1200699C Anthracyclinone derivatives and their use in amyloidosis |
| 05/11/2005 | CN1200698C Use of corneal hardening agent in enzyme orthokeratology |
| 05/11/2005 | CN1200697C Transnasal anticonvulsive compositions and modulated process |
| 05/11/2005 | CN1200696C Patch containing anti-inflammatory agent |
| 05/11/2005 | CN1200694C Solid medicaments obtained by extrusion of isomalt-containing polymer/active substance melt |
| 05/11/2005 | CN1200691C Oral solution containing galanthamine and sweetening agent |
| 05/11/2005 | CN1200690C Pressurised metered dose inhalers |
| 05/11/2005 | CN1200688C Use of sophorolipids and cosmetic and dermatological compositions |
| 05/11/2005 | CN1200687C Composition containing N-vinyl iminazole polymer or copolymer and oxidation sensitive hydrophilic active ingredients for cosmetics and/or dermatology |
| 05/11/2005 | CN1200684C Compositions comprising organosiloxane resins for delivering oral care substances |
| 05/11/2005 | CN1200673C Antimicotic nail varnish composition |
| 05/11/2005 | CA2479696A1 Use of calphostin-c to treat drug-sensitive tumor cells |
| 05/10/2005 | US6891989 Optical switch systems using waveguide grating-based wavelength selective switch modules |
| 05/10/2005 | US6891066 For therapy of cancer, restenosis, psoriasis, autoimmune disease, atherosclerosis, osteoarthritis, rheumatoid arthritis, heart failure, chronic pain, and neuropathic pain |
| 05/10/2005 | US6891063 Salts with pharmaceutically acceptable organic bases, selected from ethylenediamine, ethanolamine, diethanolamine, lysine, benzyltrimethylammonium hydroxide and tetramethylammonium hydroxide; antiinflammatory agents, wound healing agents |
| 05/10/2005 | US6891062 Pharmaceutical composition for treatment of diseases associated with decrease in bone mass |
| 05/10/2005 | US6891054 Functional acylglycerides |
| 05/10/2005 | US6891043 Inhibitors of fatty acid amide hydrolase |
| 05/10/2005 | US6891039 2-(4-Fluorophenyl)-1-(2-cyclopentylamino-4-pyrimidinyl)-5-(piperidino-N -2-ethyl)imidazo(4,5-b)pyridine, for example; MAP kinase inhibitors, for Tumor Necrosis Factor (TNF-alpha) and Interleukin-1 (IL-1) disorders such as osteoporosis |
| 05/10/2005 | US6891028 Nucleic acids encoding transferrin receptor-like proteins |
| 05/10/2005 | US6890961 Applying topically to the leukoplakia lesion an effective amount of a clear aqueous formulation comprising: water; a water miscible polyol; unsaturated fatty acid ester; a surfactant, and beta -carotene |
| 05/10/2005 | US6890959 Such as cis-(4-dimethylaminomethyl-3-hydroxy-3-(3-methoxy-phenyl)-cyclohexanone for treatment of pain, inflammation, allergies, depression, drug/alcohol abuse, gastritis, itching, cardiovascular/repiratory diseases, epilepsy, and diarrhea |
| 05/10/2005 | US6890958 Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications |
| 05/10/2005 | US6890957 Liquid formulation of metformin |
| 05/10/2005 | US6890956 Cyclohexyl sulphones as gamma-secretase inhibitors |
| 05/10/2005 | US6890954 Uses of 2-bromopalmitate in the treatment of autoimmune disease |
| 05/10/2005 | US6890952 Administering cyclic substituted aminomethyl compounds for the preparation of a drug for the treatment of pain, urinary incotinence, itching, tinnitus aurium or diarrhea in a mammal |
| 05/10/2005 | US6890951 Treatment of addiction and addiction-related behavior |
| 05/10/2005 | US6890950 Complex with cyclodextrins; antitumor, anticancer agents |
| 05/10/2005 | US6890949 Amino ceramide-like compounds and therapeutic methods of use |
| 05/10/2005 | US6890948 With an electron withdrawing substituent; Treating neoplastic diseases in methods of GDEPT, ADPET, PDEPT, VDEPT, and PDT; tissue-directed prodrug therapy |
| 05/10/2005 | US6890947 (S)-3-(1-(2-(2-chloro-phenyl)-5-methyl-oxazol-4-ylmethyl)-1H -indol-5-yl)-2-ethoxy-propionic acid; peroxisome proliferator activated receptors (PPARs) |
| 05/10/2005 | US6890946 Or conditions characterized by abnormal angiogenesis or to treat non-tumorigenic angiogenesis-dependent diseases that are characterized by abnormal growth of blood vessels |
| 05/10/2005 | US6890945 Administering a imidazo(4,5,1-ij)quinoline compound |
| 05/10/2005 | US6890943 3-acylated pyridoxal derivatives used to treat vitamin B6 deficiency, cardiovascular diseases, melanoma and other related diseases |
| 05/10/2005 | US6890942 Acyl sulfonamides as inhibitors of HIV integrase |
| 05/10/2005 | US6890941 To treat elevated serum cholesterol; atorvastatin |
| 05/10/2005 | US6890938 Antiinflammatory agents |
| 05/10/2005 | US6890937 Inhibiting the activity of one or more of MMP-2, MMP-9 and MMP-13, while exhibiting substantially less inhibitory activity against MMP-1 |
| 05/10/2005 | US6890935 Pharmaceutical compositions and methods for use |
| 05/10/2005 | US6890931 Methods of treating disorders with group I mGluR antagonists |
| 05/10/2005 | US6890930 Quinazolinones |
| 05/10/2005 | US6890929 Immunosuppressants; lupus, multiple sclerosis, skin disorders, antiarthritic agents, antihistamines, antiulcer agents, Crohn's disease |
| 05/10/2005 | US6890928 Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
| 05/10/2005 | US6890927 Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| 05/10/2005 | US6890926 Antitumor agents |
| 05/10/2005 | US6890925 Treating insulin resistance, hypertension, angina, ischemia, renal disease or Raynaud's disease, by administering pyrazole derivatives such as 1-(p-(morpholinocarbonylamino)phenyl)-3,5-di(trifluoromethyl)pyrazole |
| 05/10/2005 | US6890924 Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| 05/10/2005 | US6890922 For treatment of erectile dysfunction as well as female sexual dysfunction, incontinence, and hypertrophy of the prostate; inhibitors of cGMP-metabolizing phosphodiesterases (cGMP= cyclic guanosine monophosphate) |
| 05/10/2005 | US6890920 Therapeutic treatment of asthma, chronic obstructive pulmonary disease, rhinorrhea due to the common cold, rhinitis |
| 05/10/2005 | US6890919 Atypical antipsychotic agents having low affinity for the D2 receptor |
| 05/10/2005 | US6890918 Pharmaceutical compositions including ACE/NEP inhibitors and bioavailability enhancers |
| 05/10/2005 | US6890917 Particularly significant oral in vivo activity |
| 05/10/2005 | US6890916 Indole derivatives useful for the treatment of CNS disorders |
| 05/10/2005 | US6890915 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| 05/10/2005 | US6890914 Method of locking 1α-OH of vitamin D compounds in axial orientation |
| 05/10/2005 | US6890913 Novel chitosan of given degree of deacetylation and weight average molecular weight, production of chitosan from a fungus, and use of chitosan for treating breast or cervical cancer |
| 05/10/2005 | US6890911 Method for the treatment of inflammation |
| 05/10/2005 | US6890908 Modified ribozymes |
| 05/10/2005 | US6890907 Method of treating endobronchial infection by administering a nebulized unit dosage of an aqueous solution of tobramycin over given dosage and time, as well as specified aerosol particle sizes |
| 05/10/2005 | US6890906 Administering a compound which binds to a galectin |
| 05/10/2005 | US6890905 Increasing the availability of islet cell growth hormone to pancreatic cells wherein said islet cell growth hormone circulates at a level which is unresponsive to acute changes in glucose level. |
| 05/10/2005 | US6890904 An antiangiogenic, anticancer, and an antiproliferative which inhibits the enzyme fibroblast activation protein-alpha (FAP-alpha); peptides with reactive analog of proline where the COOH is replaced by a boronyl group (B(OH)2); val-boro-pro |
| 05/10/2005 | US6890900 Methods for treating or preventing diseases of the oral cavity |
| 05/10/2005 | US6890898 Method of regulating glucose metabolism, and reagents related thereto |
| 05/10/2005 | US6890708 Method for improving the quality of sperm for artificial insemination of animals |
| 05/10/2005 | US6890567 Sensate composition imparting initial sensation upon contact |
| 05/10/2005 | US6890561 Microencapsulated and controlled-release formulations of isoflavone from enriched fractions of soy and other plants |
| 05/10/2005 | US6890558 Anticarcinogenic liquid comprising vinorelbine or vinorelbine ditartrate salt, ethanol, water, glycerol |
| 05/10/2005 | US6890557 A film forming emulsions comprising triglycerides, cholesterol, phospholipids, an charged lipid, and water; drug delivery with an apoprotein, deliverying nucleic acid, a gene therapy |
| 05/10/2005 | US6890555 Liposome compositions of porphyrin photosensitizers |
| 05/10/2005 | US6890554 Genetic immunization with cationic lipids |
| 05/10/2005 | US6890550 Method of preventing parturient hypocalcemia in animals and compositions used therein |
| 05/10/2005 | US6890549 Reducing levels of bioavailable fat by adminstering alpha-cyclodextrin |
| 05/10/2005 | US6890546 Stents, catheters, arterio-venous grafts, by-pass grafts and drug delivery ballons with surface coating containing a rapamycin derivative having a tetrazole group |
| 05/10/2005 | US6890526 Diagnosis, monitoring, and treatment of multiple sclerosis. The invention is based in part on the discovery that Chlamydia is present in patients with multiple sclerosis, and that anti-chlamydial agents improve or sustain neurological |
| 05/10/2005 | US6890523 Administering a polymer with pendant acid functional groups or a salt with a pharmaceutically acceptable cation; free of acid anhydride groups; antidiarreah agents |
| 05/10/2005 | US6890517 A liquid, propellant-free mixtures for treating asthma or chronic obstructive pulmonary disease; tiotropium bromide |
| 05/10/2005 | US6890344 Positively charged biocompatible substance, such as biopolymers of glucosamine, combine with negatively charged blood cells |
| 05/10/2005 | CA2407562C Tryptophan source from plants and uses therefor |
| 05/10/2005 | CA2363451C Oilseed processing |
| 05/10/2005 | CA2320474C 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino]purines |
| 05/10/2005 | CA2303801C Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists |
| 05/10/2005 | CA2278290C Quinazolinone compounds |
| 05/10/2005 | CA2251987C Microparticles |
| 05/10/2005 | CA2250569C Novel phenanthridines substituted in the 6 position |
| 05/10/2005 | CA2234247C An agent for curing ophthalmological diseases |
| 05/10/2005 | CA2191815C Heterocyclic compounds having tachykinin receptor antagonist activity, their preparation and their use |
| 05/10/2005 | CA2183367C Ready-to-use indomethacin collyre |
| 05/10/2005 | CA2166332C Antiglucocorticoid steroids for the treatment of anxiety disorders |
| 05/10/2005 | CA2153856C Duloxetine enteric pellets |
| 05/10/2005 | CA2111193C Tissue treatment composition comprising fibrin or fibrinogen and biodegradable and biocompatible polymer |
| 05/10/2005 | CA2097044C Cyclopentane- and -pentene-.beta.-amino acids |
| 05/10/2005 | CA2025298C Novel process for the preparation of lipidic microparticulates |
| 05/10/2005 | CA1341482C Process for preparing fragments of aids-associated retroviruses |
| 05/07/2005 | CA2483920A1 A method of treating premenstrual dysphoric disorder with escitalopram |
| 05/07/2005 | CA2460384A1 Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations |
| 05/06/2005 | WO2005040833A1 Regulation of human metastin recognising receptors |
| 05/06/2005 | WO2005040758A2 Use of pirfenidone in therapeutic regimens |
| 05/06/2005 | WO2005040378A1 Nucleic acids useful for triggering tumor cell lethality |